GlaxoSmithKline’s bid for Human Genome Sciences cleared, but rejected by HGS Board
The Hart-Scott-Rodino waiting period for GlaxoSmithKline’s (GSK) tender offer for Human Genome Sciences (HGS) has expired. Human Genome Sciences is a Rockville, MD-based biopharmaceutical corporation. Under the terms of the offer, GSK would buy all outstanding shares of HGS for $13/share in cash.
However, the HGS Board of Directors has rejected the offer as inadequate and urged shareholders to reject the offer as well. According to the HGS press release in response to the HSR termination announcement, GSK’s tender offer was unsolicited and “seeks to circumvent, disrupt and prematurely end [HGS’s] strategic review process.
Full content: MarketWatch
Related content: New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions (Janet McDavid & Eric Stock, Hogan Lovells)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
US Judge OKs $110 Million Settlements in Antitrust Case Against Major Real Estate Brokerages
Oct 31, 2024 by
CPI
50 States and Territories Reach $49.1 Million Settlement in Generic Drug Price-Fixing Case
Oct 31, 2024 by
CPI
OpenAI Enhances ChatGPT with New Search Feature, Challenging Google’s Dominance
Oct 31, 2024 by
CPI
First Circuit Hears Arguments on Whether Federal Baseball Antitrust Exemption Shields Puerto Rican League from Legal Claims
Oct 31, 2024 by
CPI
Federal Appeals Court Expresses Doubts Over FCC’s Authority in Net Neutrality Revival
Oct 31, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI